Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation

Contributed by: PR Newswire

Tags

HANSA-BioPhrma

More Like This

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA

Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial

Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation